Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Erythromycin estolate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin ethylsuccinate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin stearate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin ophthalmic agent |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin lactobionate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin gluceptate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin phosphate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin measurement |
Component |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Accidental erythromycin poisoning |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Intentional erythromycin poisoning |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
intoxication par l'érythromycine d'intention indéterminée |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin adverse reaction |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin overdose |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Accidental erythromycin overdose |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Intentional erythromycin overdose |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
surdose d'érythromycine d'intention indéterminée |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing erythromycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 250 mg gastro-resistant oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 125mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 250mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 500mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin (as erythromycin lactobionate) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin (as erythromycin ethyl succinate) 25 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 100 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin [2] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin [skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 20 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 3% in benzoyl peroxide topical gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 40 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 40 mg/g and tretinoin 250 microgram/g cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing erythromycin in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin 333 milligram/1 each gastro-resistant oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 333mg polymer coated particle tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 500mg polymer coated particle tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 250mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 2% gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin 20 microgram/1 milligram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 15 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 20mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 500 mg gastro-resistant oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Benzoyl peroxide + erythromycin 50mg/30mg gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin ethylsuccinate + sulfisoxazole acetyl ns/ns suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Allergy to erythromycin |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing erythromycin and isotretinoin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin + Tretinoin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin- and zinc acetate-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Benzoyl peroxide- and erythromycin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 20 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 500mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 250mg e/c granules in capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely erythromycin 20 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Accidental erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Intentional erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin adverse reaction |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin sensitivity |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing erythromycin in ophthalmic dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Allergy to erythromycin |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 500mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 500mg tablet (substance) |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely erythromycin (as erythromycin stearate) 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin (as erythromycin stearate) 500 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin dihydrate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin propionate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin lactobionate |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin dihydrate (substance) |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin phosphate |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin propionate (substance) |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin stearate |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin gluceptate |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin ethylsuccinate (substance) |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin estolate |
Is modification of (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 250mg gastro-resistant oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Erythromycin 250 mg gastro-resistant oral tablet |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 250 mg gastro-resistant oral tablet |
Has precise active ingredient |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 500mg tablet (substance) |
Has precise active ingredient |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely erythromycin (as erythromycin lactobionate) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 100 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin (as erythromycin ethyl succinate) 25 mg/mL oral suspension |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 20 mg/mL cutaneous solution |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 20 mg/mL cutaneous solution |
Has precise active ingredient |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 20 mg/g cutaneous gel |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 20 mg/g cutaneous gel |
Has precise active ingredient |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 40 mg/g cutaneous gel |
Has basis of strength substance (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 40 mg/g cutaneous gel |
Has precise active ingredient |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin 40 mg/g and tretinoin 250 microgram/g cutaneous solution |
Has precise active ingredient |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Erythromycin 40 mg/g and tretinoin 250 microgram/g cutaneous solution |
Has basis of strength substance (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
Has precise active ingredient |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
Has basis of strength substance (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
Has basis of strength substance (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
Has precise active ingredient |
False |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing erythromycin and sulfafurazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Erythromycin-containing product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing erythromycin in cutaneous dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |